Multiple Sclerosis and Related Disorders

Papers
(The TQCC of Multiple Sclerosis and Related Disorders is 6. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
Test-retest reliability of the Swedish version of the Modified Fatigue Impact Scale in people with mild to moderate multiple sclerosis75
Preliminary race-ethnicity-based analyses of fall risk among people with multiple sclerosis61
Characteristics of Patients with Newly Diagnosed Multiple Sclerosis: A Five-Year Study at Benghazi Medical Center, Benghazi, Libya60
Real-World Evidence with Five-Year Data (2017-2022) on the Use of Cladribine Tablets in Patients with Multiple Sclerosis in England: an Updated Analysis from the CLARENCE Study59
EDSS and Infratentorial White Matter Lesion Volume are Considered Predictors of Fatigue Severity in RRMS53
Influence of Cigarette, and Waterpipe Smoking, Alcohol, and Drug Consumption on the Occurrence of Late-Onset Multiple Sclerosis49
Comparison of SARS-CoV-2 antibody response after two doses of mRNA and inactivated vaccines in multiple sclerosis patients treated with disease-modifying therapies48
A one year follow of patients with multiple sclerosis during COVID-19 pandemic: A cross-sectional study in Qom province, Iran47
Markers of Epstein-Barr virus and Human Herpesvirus-6 infection and multiple sclerosis clinical progression47
Evaluation of adherence to treatment in patients with multiple sclerosis from Latin America46
Plasma 24-hydroxycholesterol is associated with narrower common carotid artery and greater flow velocities in relapsing multiple sclerosis41
“It's on the tip of my tongue!” exploring confrontation naming difficulties in patients with multiple sclerosis41
Diagnosing ‘transition’ to secondary progressive multiple sclerosis (SPMS): A step-by-step approach for clinicians41
Peripheral nerve vulnerability as risk factor for multiple sclerosis: Possible insights from Neurofibromatosis type 2 (NF2)40
Leber Hereditary Optic Neuropathy Presenting as Bilateral Visual Loss and White Matter Disease40
Involvement Peripheral Nerve System in Multiple Sclerosis40
The Use of Ocrelizumab in Pediatric Multiple Sclerosis Patients in the United Arab Emirates: A Retrospective Study38
The Relationship Between Smoking and Multiple Sclerosis Severity in Saudi Arabia37
Effects of constraint induced movement therapy in patients with multiple sclerosis: A systematic review37
Risk factors for development of lymphopenia in dimethyl fumarate-treated patients with multiple sclerosis36
Clinical and imaging features of patients with late-onset myelin oligodendrocyte glycoprotein antibody-associated disease35
Expert Opinion on COVID-19 Vaccination and the Use of Cladribine Tablets35
Index of cardiac-electrophysiological balance in relapsing–remitting multiple sclerosis patients treated with fingolimod34
Anti-Spike IgG in multiple sclerosis patients after BNT162b2 vaccine: An exploratory case-control study in Italy34
Functional electrical stimulation combined with voluntary cycling accentuates VO2 response in people with severe multiple sclerosis: A pilot study34
Characteristics of recurrence risk perception and coping strategies in patients with neuromyelitis optica spectrum disorder: A qualitative study34
Reconciling lesions, relapses and smouldering associated worsening: A unifying model for multiple sclerosis pathogenesis34
Trait mindfulness, emotion dysregulation, and depression in individuals with multiple sclerosis34
Coexistence of epilepsy or seizure and multiple sclerosis; a single center experience34
Impact of insurance status on MRI phenotypes in MS33
143. Navigating the Maze of Multiple Sclerosis Disease Modifying Therapies: Insights from Iran's National MS Registry33
57. Cognitive Decline and Motor Handicap in Multiple Sclerosis Patients33
Lipid measures are associated with cognitive functioning in multiple sclerosis patients32
125. Investigating Psychoses in Pediatric-Onset Multiple Sclerosis: A Systematic Review of Case Reports32
157. Remibrutinib Exposure in Cerebrospinal Fluid: Insights from a Study in Healthy Subjects32
Symptoms of PTSD and depression in newly diagnosed people with multiple sclerosis during the outbreak Oct.7th war on Gaza: A case-control study from Jordan31
Markedly elevated cerebrospinal fluid white blood cell count in multiple sclerosis: How high is too high?31
Can neurofilament lightchain as endpoint in Phase 2 derisk clinical disability worsening in Phase 3 in multiple sclerosis?30
Incidence of multiple sclerosis relapses and pseudo-relapses following COVID-19 vaccination30
Siponimod following Alemtuzumab in secondary progressive MS: investigating sequential therapy–A case series29
Multiple sclerosis disease-modifying therapy use in the department of veteran affairs and Medicare: A comparative analysis28
Self-reported cognitive function mediates the relationship between employment status and cognitive functioning in persons with multiple sclerosis28
Discontinuation of first-line disease-modifying therapy in relapse onset multiple sclerosis28
Characterizing causal relationships of visceral fat and body shape on multiple sclerosis risk28
Macular vascular density alteration patterns in paediatric optic neuritis patients with serum MOG antibody positivity detected by optic coherence tomography angiography28
Incidence of malignant neoplasms and mortality in people affected by multiple sclerosis in the epoch of disease-modifying treatments: A population-based study on Tuscan residents27
Relationship between cognitive disturbances and sleep disorders in multiple sclerosis is modulated by psychiatric symptoms27
Reliability of mobile video-oculography in multiple sclerosis patients using an iPad: A prospective validation study27
Identification of common susceptibility genes and drug target genes in multiple sclerosis, systemic lupus erythematosus, and rheumatoid arthritis and its value to guide clinical treatment27
Evaluation of the use of high-efficacy treatments (HETs) in patients with relapsing-remitting multiple sclerosis in Argentina26
S1P receptor modulators in Multiple Sclerosis: Detecting a potential skin cancer safety signal26
Feasibility and usability evaluation of a gamified fatigue management mobile application for persons with multiple sclerosis in everyday life26
Sexual Dysfunctions and Self-Esteem in Multiple Sclerosis: A Tunisian Study26
A critical evaluation of machine learning approaches for screening depression and anxiety in early multiple sclerosis26
Sarcopenia in patients with multiple sclerosis25
Sexual problems in MS: Sex differences and their impact on quality of life25
Cognitive outcomes in late-onset versus adult-onset Multiple Sclerosis25
Epidemiology of familial multiple sclerosis and its comparison to sporadic form in Markazi Province, Iran25
The effects of bupropion on sexual dysfunction in female patients with multiple sclerosis: A double-blind randomized clinical trial25
The Management of Lower Urinary Tract Symptoms in Multiple Sclerosis: an Umbrella Review24
The relationship between cognitive impairment, cognitive fatigue, and visual evoked potential latency in people with multiple sclerosis24
Prognostic factors of tumefactive demyelinating lesions and differential features for multiple sclerosis in etiology24
How Much Is Enough? Determining Minimum Valid Tracking Periods for Reliable Physical Activity Monitoring24
Atherosclerosis and multiple sclerosis: An overview on the prevalence of risk factors24
Glucagon-like peptide-1 agonist safety and efficacy in a multiple sclerosis cohort24
Psychometric measurement properties and reference values of the six-spot step test, the six-minute walk test, the 25-foot walk test, and the 12-item multiple sclerosis walking scale in people with mul24
Cladribine effects on emotional awareness and reasoning: The CLEAR study23
Real World Study of Ocrelizumab in Multiple Sclerosis: Kuwait Experience23
Effects of submotor-threshold tibial nerve stimulation on plantarflexion torque in healthy adults and people with multiple sclerosis23
Carotid intima media thickness and multiple sclerosis23
Prevalence and Clinical Characteristics of Urological Symptoms in Iranian Multiple Sclerosis Patients: Implications for Quality of Life and Management23
Multiple Sclerosis in Elderly Patients: When We Can Stopped Treatment?23
Management of patients with active relapsing-remitting or secondary progressive multiple sclerosis: A French real-world study based on claims data linked to a phase IV study23
Dysphagia in Relation with Depression, Anxiety, Fatigue, Sleep Quality, and Pain in Multiple Sclerosis23
Perspectives on fatigue management among veterans living with multiple sclerosis23
Predictors of Progression of Multiple Sclerosis in a Sample of Egyptian Patients23
The role of pregnancy in relapsing-remitting MS prognosis: A five-year study23
Clinical risk stratification: Development and validation of the DAAE score, a tool for estimating patient risk of transition to secondary progressive multiple sclerosis23
RETRACTED: New relapse of multiple sclerosis and neuromyelitis optica as a potential adverse event of AstraZeneca AZD1222 vaccination for COVID-1922
Real-World Use of Cladribine Tablets (Completion Rates and Treatment Persistence) in Patients with Multiple Sclerosis in England: the CLARENCE Study22
Telehealth in Multiple Sclerosis: Fostering Quality of Life22
Depression, Anxiety and Alexithymia in Tunisian Patients with Multiple Sclerosis22
Dynamic disability measures decrease the clinico-radiological gap in people with severely affected multiple sclerosis22
Pregnancy and Infant Outcomes in Women Receiving Ocrelizumab for the Treatment of Multiple Sclerosis: Analysis of the Largest Available Outcomes Database22
Cervical lymph node diameter reflects disease progression in multiple sclerosis22
Central American and Caribbean consensus for the treatment of MS, NMOSD, and MOGAD22
Implementing Shared Decision-Making for Multiple Sclerosis: The MS-SUPPORT Tool22
The Effect of Rituximab on Mood Disorders in Multiple Sclerosis21
Validation of the Self-Assessed Dynamic Gait Index in People with Multiple Sclerosis21
Is BDNF related to spatial-temporal gait parameters in people with multiple sclerosis? An observational study21
Using MS induced pluripotent stem cells to investigate MS aetiology21
Bio-Psycho-Social Model of Multiple Sclerosis (BPSMMS)21
Barriers to Engage in Physical Activity in People with Multiple Sclerosis in Jordan21
Monkeypox in Multiple Sclerosis patients: Should we be alert?21
Response: Treatment of multiple sclerosis as a single disease based on the body-pathology-environment model21
Cross-Cultural Adaptation and Psychometric Evaluation of the Physical Activity and Disability Survey - Revised in People with Multiple Sclerosis21
Influence of physicians’ risk perception on switching treatments between high- efficacy and non–high-efficacy disease‑modifying therapies in multiple sclerosis20
Levamisole-associated multifocal inflammatory encephalopathy: clinical and MRI characteristics, and diagnostic algorithm20
Exploratory clinical efficacy and patient-reported outcomes from NOVA: A randomized controlled study of intravenous natalizumab 6-week dosing versus continued 4-week dosing for relapsing-remitting mul20
A systematic review and meta-analysis on gene-environment interaction effects on the associations of vitamin D and sun exposure with multiple sclerosis risk20
Practical issues concerning the use of Magnetic Resonance Imaging in Multiple Sclerosis in Latin America: Discussion from 16 centres on behalf of the Foro Latam EM Study Group20
Natalizumab treatment of multiple sclerosis — a Danish nationwide study with 13 years of follow-up20
Efficacy of Virtual Reality Interventions on Mood and Cognition in Patients with Multiple Sclerosis. a Systematic Review20
Tixagevimab and Cilgavimab (Evusheld) Boosts Antibody Levels to SARS-Cov-2 in Patients with Multiple Sclerosis on B-Cell Depleters20
Glial-mediated pathogenesis and intervention strategies in neuromyelitis optica spectrum disorder20
Effects of inspiratory muscle training on balance, trunk control, fear of falling, respiratory function, and quality of life in people with multiple sclerosis: a randomized controlled trial20
Cytokines/chemokines and soluble immune checkpoint molecules in anti-GABAB receptor encephalitis20
Higher frequency of Human herpesvirus-6 (HHV-6) viral DNA simultaneously with low frequency of Epstein-Barr virus (EBV) viral DNA in a cohort of multiple sclerosis patients from Rio de Janeiro, Brazil20
Patients experiences when receiving diagnosis of multiple sclerosis: A qualitative systematic review20
Peripheral neuropathy and MOG-IgG: A clinical and neuropathological retrospective study20
70. Real-World Experience of Cladribine Tablets in the Treatment of Multiple Sclerosis: An Omani Cohort from Khoula Hospital19
41. Neuropathic Pain in Multiple Sclerosis19
23. Vanishing Clues: A Systematic Review of Oligoclonal Band Disappearance in Multiple Sclerosis Patients after Treatment19
165. Unmet Needs and Treatment of Relapsing-Remitting Multiple Sclerosis in Saudi Arabia: Focus on the Role of Ofatumumab19
95. Patterns of Corpus Callosum Lesions in Demyelinating Diseases of the Central Nervous System19
30. Thalamic Volume Differentiates Multiple Sclerosis from Neuromyelitis Optica Spectrum Disorder19
81. Gender Difference In Egyptian Patients With Multiple Sclerosis19
134. Impact of Bowel Dysfunction, Urinary Dysfunction, and Fatigue on Quality of Life in Multiple Sclerosis19
101. Pseudotumor Demyelinating Lesions in Inflammatory Diseases of the Central Nervous System: An Algerian Series19
120. The Pathological Findings of the First Cervical Spine MRI of The Neuromyelitis Optica Spectrum Disorders Patients19
67. Domain-Specific and Global Cognitive Impairment in Multiple Sclerosis Patients Based on Cambridge Neuropsychological Test Automated Battery19
Neurological efficacy and safety of mesenchymal stem cells (MSCs) therapy in people with multiple sclerosis (pwMS): An updated systematic review and meta-analysis18
Seroconversion after COVID-19 vaccination for multiple sclerosis patients on high efficacy disease modifying medications18
Quantifying the economic burden to patients of relapse events from neuromyelitis optica spectrum disorders: A cross-sectional survey18
Microstructural alterations in different types of lesions and their perilesional white matter in relapsing-remitting multiple sclerosis based on diffusion kurtosis imaging18
Efficacy and safety of ocrelizumab in pediatric multiple sclerosis18
Smartphone monitoring of cognition in people with multiple sclerosis: A systematic review18
Significant upregulation of prenyltransferase-related genes in neuromyelitis optica: Diagnostic potential and clinical correlations18
Impact of multiple sclerosis on male sexual and reproductive health18
Effect of high frequency repetitive transcranial magnetic stimulation (rTMS) on the balance and the white matter integrity in patients with relapsing-remitting multiple sclerosis: A long-term follow-u18
Capacity of fullerenols to modulate neurodegeneration induced by ferroptosis: Focus on multiple sclerosis18
Exclusion of alternative diagnoses: A component of the 2023 MOGAD criteria that belongs at the forefront, not in the background18
No difference in radiologic outcomes for natalizumab patients treated with extended interval dosing compared with standard interval dosing: Real-world evidence from MS PATHS18
Clinical and MRI predictors of cognitive decline in patients with relapsing-remitting multiple sclerosis: A 2-year longitudinal study18
Significant retinal microvascular impairments in multiple sclerosis assessed through optical coherence tomography angiography18
Switching from natalizumab to an anti-CD20 monoclonal antibody in relapsing remitting multiple sclerosis: A systematic review18
Discontinuation of dimethyl fumarate in multiple sclerosis - a nationwide study18
Evaluation of functional outcome measures after fampridine treatment in patients with multiple sclerosis - An interventional follow-up study18
Upper cervical cord atrophy is independent of cervical cord lesion volume in early multiple sclerosis: A two-year longitudinal study18
Low intensity interval robot-assisted gait training improves mobility in people with progressive multiple sclerosis: the PROGR-EX randomized controlled trial18
Effect of immersive virtual reality training on hand-to-mouth task performance in people with Multiple Sclerosis: A quantitative kinematic study17
Efficacy and safety of ocrelizumab in patients with relapsing multiple sclerosis: Real-world experience of two Swiss multiple sclerosis centers17
MS in the UAE: Population Estimates of Anxiety, Depression and Health-Related Quality of Life17
Multiple Sclerosis and biological definitions in neurodegenerative diseases17
106. Assessment of Depression and Anxiety in Patients with Multiple Sclerosis in Morocco17
Factors contributing to falls in people with multiple sclerosis: The exploration of the moderation and mediation effects17
Aerobic exercise increases irisin serum levels and improves depression and fatigue in patients with relapsing remitting multiple sclerosis: A randomized controlled trial17
Effects of photobiomodulation therapy on muscle function in individuals with multiple sclerosis17
Cerebrospinal fluid indices as predictors of treatment response in autoimmune encephalitis17
Early use of high efficacy therapies in pediatric forms of relapsing-remitting multiple sclerosis: A real-life observational study17
Social network size and mental health outcomes in youth with neuroinflammatory disorders17
79. Sustained Treatment Persistence and High Adherence to Cladribine Tablets in Multiple Sclerosis: Results from Patient Support Program in Gulf Countries17
Assessing disability progression using the WHODAS 2.0 in multiple sclerosis: Investigating clinical and socio-demographic factors in a large longitudinal cohort study (TONiC-MS)17
Association between clinical characteristics, acute steroid treatment and oligoclonal bands result in multiple sclerosis: A retrospective study17
Traditional first-line treatment failure rates in neuromyelitis optica spectrum disorder patients included in the Argentinean registry (RelevarEM)17
Asymptomatic MRI lesions in pediatric-onset AQP4-IgG positive NMOSD17
Association of health behaviour and clinical manifestation in early multiple sclerosis in Germany – Baseline characteristics of the POWER@MS1 randomised controlled trial17
The prevalence and clinical phenotype of dual seropositive neuromyelitis optica spectrum disorders at a national reference center in South Asia17
Weak grip strength among persons with multiple sclerosis having minimal disability is not related to agility or integrity of the corticospinal tract17
153. Efficacy and Safety of Tolebrutinib Versus Placebo in Non-Relapsing Secondary Progressive Multiple Sclerosis: Results From the Phase 3 HERCULES Trial17
124. The Prevalence of Iron Overload in Patients with Multiple Sclerosis in National Guard Health Affair Hospital, Riyadh Center from 2015-202117
Optical coherence tomography and visual evoked potential and its relationship with neurological disability in patients with relapsing-remitting multiple sclerosis17
Adherence to Treatment in Multiple Sclerosis17
Seasonal variation in attacks of neuromyelitis optica spectrum disorders and multiple sclerosis: Evaluation of 794 attacks from a nationwide registry in Argentina17
Coenzyme Q10 supplementation in multiple sclerosis; A systematic review16
SARS-CoV-2 infection in patients with neuroimmunological disorders in a tertiary referral centre from the north of Portugal16
Beyond the B-cell as a treatment target in multiple sclerosis16
Prevalence of Urinary Tract Symptoms in Patients with Multiple Sclerosis and Health Care Seeking Behavior: A Cross Sectional Study in Riyadh, Saudi Arabia.16
Neural Substrates of Mobility and Postural Impairments in People with Multiple Sclerosis16
Effects of Cognitive and Motor Secondary Tasks on Gait Performance in Healthy Controls and Multiple Sclerosis Patients with and Without Fall History16
Are we ready for CD19-targeted CAR T-cell therapies in MS?16
High-efficacy therapy reduces subcortical grey matter volume loss in Japanese patients with relapse-onset multiple sclerosis: A 2-year cohort study16
Telemedicine and Multiple Sclerosis Management in the Era of COVID-19, Al-Azhar Experience16
Transcranial direct current stimulation for spasticity in patients with multiple sclerosis: Exploring novel routes16
The effect of COVID-19 lockdowns on exercise and the role of online exercise in Australians with multiple sclerosis16
Reduced physical activity in multiple sclerosis: The role of gait parameters, gait variability parameters and self-reported measure of gait16
Linking X to MS: Immunity and demyelination on the X-chromosome in MS16
Effectiveness and safety of switching to teriflunomide in older patients with relapsing multiple sclerosis: A real-world retrospective multicenter analysis16
Navigating the discontinuation of multiple sclerosis first line treatments: A paradigm shift in patient care16
Clinical characteristics, sero- prevalence, treatment and outcomes of AQP4 IgG associated neuromyelits optic spectrum disorder (NMOSD) in Sri Lanka16
The serum kynurenine pathway metabolic profile is associated with overweight and obesity in multiple sclerosis16
Psychotherapy and professional psychological support in multiple sclerosis: Uncovering patients’ patterns of access and preferences16
Quality of life, Knowledge and Access to Treatment in Times of Economic crisis in Lebanon16
Self-reported fatigue impact is associated with frequency of falls and injurious falls in people with multiple sclerosis16
Emerging trends in multiple sclerosis research16
Clinical Characteristics of Switching Between Disease Modifying Drugs Among a Sample of Egyptian Multiple Sclerosis Patients16
Pregnancy Outcomes in Patients with Multiple Sclerosis Following Exposure to Ofatumumab16
COVID-19 in neuromyelitis optica spectrum disorder patients in Poland16
Range of motion abnormalities in the lower limb joints during gait in youth with multiple sclerosis16
Aggressive Pediatric Multiple Sclerosis: Features and therapeutic Challenges16
Hypogonadism in men with multiple sclerosis: Prevalence and clinical associations16
Multiple Sclerosis in Middle East North Africa (MENA) Region: Challenges, Achievements and Opportunities.16
Comparative efficacy and safety of ozanimod and ponesimod for relapsing multiple sclerosis: A matching-adjusted indirect comparison16
Increased healthcare utilization in the year before multiple sclerosis diagnosis16
Serum neurofilament light chain levels suggest neuroprotection following bexarotene-induced remyelination in people with relapsing remitting multiple sclerosis15
Seizures in inflammatory demyelinating disorders of the central nervous system15
Serum ocrelizumab concentrations in patients with multiple sclerosis: A cross-sectional study from routine healthcare15
Early predictive risk factors for dimethyl fumarate-associated lymphopenia in patients with multiple sclerosis15
Connection between microstructural alterations detected by diffusion MRI and cognitive dysfunction in MS: A model-free analysis approach15
Allied health professionals knowledge and clinical practice in telehealth exercise behavioural change for multiple sclerosis15
Racial disparities in hypertension management among multiple sclerosis patients15
Understanding use and predictors of compensatory cognitive strategies in people with multiple sclerosis15
Hospitalisations and humoral COVID-19 vaccine response in vaccinated rituximab-treated multiple sclerosis patients15
Serum Oxidative Stress Biomarkers in Relapsing Remitting Multiple Sclerosis Patients with No Evidence of Disease Activity15
Evaluating the impact of systematic reporting of patient-reported outcome measures on depression and anxiety levels in people with multiple sclerosis: a randomized controlled trial15
Burden of multiple sclerosis: impact on the patient, family and society15
Unwrapping the “black box” of balance training in people with multiple sclerosis – A descriptive systematic review of intervention components, progression, and intensity15
Feasibility and tolerability of portable, low-field brain MRI for patients with multiple sclerosis15
Effect of siponimod on retinal thickness, a marker of neurodegeneration, in participants with SPMS: Findings from the EXPAND OCT substudy15
Investigating treatment alternatives for fingolimod in patients with multiple sclerosis developed refractory fingolimod-related genital Human Papilloma Virus (HPV) infection15
Serum Neurofilament Light Chain as a Biomarker of Disease Progression in a Sample of Egyptian Multiple Sclerosis Patients15
Prevalence and incidence of multiple sclerosis in the Netherlands15
S3I-201, a selective stat3 inhibitor, ameliorates clinical symptoms in a mouse model of experimental autoimmune encephalomyelitis through the regulation of multiple intracellular signalling in Th1, Th15
Long term effects of continuous positive airway pressure treatment of obstructive sleep apnea-hypopnea syndrome in multiple sclerosis patients15
Ocrelizumab during pregnancy and lactation: Rationale and design of the MINORE and SOPRANINO studies in women with MS and their infants14
Clinical features of MOGAD with brainstem involvement in the initial attack versus NMOSD and MS14
Validity and reliability of the Six-Minute Pegboard Ring Test for assessing functional capacity and upper limb function in persons with multiple sclerosis14
Serum neurofilament light chain as a biomarker in multiple sclerosis: A cross-sectional observation in real-world clinical practice14
Persistently reduced humoral and sustained cellular immune response from first to third SARS-CoV-2 mRNA vaccination in anti-CD20-treated multiple sclerosis patients14
Effects of six-month home-based neuro-functional and resistance training interventions on cognitive and motor performance in multiple sclerosis patients with cognitive impairment: A randomized control14
Mesenchymal stem cells in clinical trials for multiple sclerosis: A systematic literature review and review of clinical trials14
Assessment of changes in fatigue and cognitive functioning in the absence of progression independent of relapse activity14
Altered gene expression of miR-155 in peripheral blood mononuclear cells of Multiple sclerosis patients: Correlation with TH17 frequency, inflammatory cytokine profile and autoimmunity14
Deciphering the bidirectional impact of leukocyte telomere length on multiple sclerosis progression: A Mendelian randomization study14
MRI-based radiomics for differention of aquaporin 4-immunoglobulin G–positive neuromyelitis optic spectrum disorder and anti myelin oligodendrocyte glycoprotein immunoglobulin G–associated disorder14
Risk of COVID-19 infection and severe disease in MS patients on different disease-modifying therapies14
Humoral response to COVID-19 vaccination in MS patients on disease modifying therapy: Immune profiles and clinical outcomes14
Comparison of vision-related quality of life in NMOSD and MOGAD14
Variability of objective gait measures across the expanded disability status scale in people living with multiple sclerosis: A cross-sectional retrospective analysis14
Effectiveness of acceptance and commitment therapy for improving quality of life and mood in individuals with multiple sclerosis: A systematic review and meta-analysis14
The influence of manual dexterity on processing speed assessment in multiple sclerosis: A comparison of the PST and oral SDMT14
The influence of disease-modifying therapy on hidden disability burden in people with newly diagnosed relapsing-remitting multiple sclerosis14
Preferences for neuromyelitis optica spectrum disorder treatments: A conjoint analysis with neurologists in Spain14
Physical activity is associated with fatigue in persons newly diagnosed with multiple sclerosis14
A cross-sectional analysis of persistence to disease-modifying therapies in treatment naïve and experienced patients with relapsing multiple sclerosis at a health-system specialty pharmacy14
Sleep, physical activity, and psychological outcomes in children and adolescents with pediatric onset multiple sclerosis14
Clinical risk factors for recurrence of myelin oligodendrocyte glycoprotein antibody-associated disease14
Prognosis of walking function in multiple sclerosis supported by gait pattern analysis14
Additive beneficial effects of aerobic training and royal jelly on hippocampal inflammation and function in experimental autoimmune encephalomyelitis rats14
Patient-reported quality of life and perceived disease burden in mexican patients with neuromyelitis optica spectrum disorder: a cross-sectional analysis14
Archetypal analysis of visual fields in optic neuritis reveals functional biomarkers associated with outcome and treatment response14
Systematic review on the wearing-off phenomenon of disease-modifying therapies in managing multiple sclerosis14
Neuroprotective role of high dose Vitamin D supplementation in multiple sclerosis: Sub-analysis of the EVIDIMS trial13
Comprehensive analysis of multiple sclerosis hospitalization trends in Spain (1998–2022)13
Alemtuzumab-induced thyroid disease: A Danish cohort study13
150. Frexalimab in Relapsing Multiple Sclerosis and Non-Relapsing Secondary Progressive Multiple Sclerosis: Design of Phase 3 Frexalt and Freviva Trials13
An evaluation of the role of community care in meeting the needs of people with multiple sclerosis in Ireland13
Frequency and risk factors of rebound after fingolimod discontinuation – A retrospective study13
The practical uses of serum neurofilament light chain as a biomarker in multiple sclerosis13
Sex differences in multiple sclerosis treatment with disease modifying drugs: a step towards gender neurology13
0.25401902198792